Compare Neurocrine Biosciences Inc (NBIX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Prospect Capital Corporation — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Prospect Capital Corporation trades at $2.18 (market cap $1.12B). The key difference: Neurocrine Biosciences Inc is far larger — about 15.5× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.42% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PSEC | |
|---|---|---|
Market Cap | $17.40B | $1.12B |
Sector | Health | Financials |
52-Week High | $180.55 | $3.47 |
52-Week Low | $123.10 | $2.15 |
Enterprise Value | $16.49B | — |
Dividend Yield | — | 22.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Prospect Capital Corporation (PSEC) trades at $2.15, down 4.44% on the day, reflecting persistent bearish technical signals. The company's fundamentals are challenged, with negative revenue of -$407M and a net income margin of -495.94% for 2025, though it has beaten EPS estimates for the last three consecutive quarters. Recent corporate actions include regular dividend payments, while news highlights portfolio activity and deep discounts to net asset value.
The outlook remains cautious due to weak profitability and a bearish analyst consensus. The primary opportunity lies in the stock's high yield and significant discount to book value, but risks include ongoing revenue volatility, declining net asset value, and skepticism about portfolio quality. Investors should weigh income potential against fundamental deterioration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
